Splenic follicular B cells promote adverse cardiac remodeling after myocardial infarction via MHC II-dependent antigen presentation.

This study demonstrates that splenic follicular B cells drive adverse cardiac remodeling after myocardial infarction by presenting cardiac-derived peptides via MHC class II to modulate myocardial T-cell responses, identifying this antigen-presentation pathway as a novel therapeutic target for ischemic heart failure.

The Gist

The Big Picture: A Case of Mistaken Identity

Imagine your heart is a bustling city. When a heart attack (myocardial infarction) happens, it's like a massive earthquake hitting that city. Naturally, the city calls for emergency services (the immune system) to clean up the rubble and start rebuilding.

Usually, this cleanup crew is helpful. But in this study, the researchers discovered that a specific group of "security guards" (immune cells) living in a nearby town (the spleen) are actually making the damage worse. They are so confused by the earthquake that they start attacking the city they are supposed to protect, leading to long-term heart failure.

The Characters: The Spleen and the B-Cells

• The Spleen: Think of this as a massive warehouse or training camp for the body's immune system. It stores millions of immune cells waiting to be deployed.
• The B-Cells: These are the security guards stationed in the warehouse. Their normal job is to spot invaders (like bacteria) and sound the alarm.
• The MHC II: This is the ID card scanner or the megaphone the guards use. It allows them to show a piece of "evidence" (an antigen) to other cells so everyone knows what the enemy looks like.

The Story Unfolds

1. The Earthquake (Heart Attack)
When a heart attack occurs, heart tissue is damaged. Pieces of the heart (proteins) leak out into the bloodstream.

2. The Confused Guards
The immune system rushes to the spleen (the warehouse). The B-cells there grab these leaking heart proteins, thinking they are foreign invaders. They load these heart proteins onto their MHC II scanners (ID cards).

3. The Wrong Alarm
These confused B-cells travel from the spleen back to the heart. They act like security guards who have been tricked into thinking the city's own buildings are terrorists. They present the "heart protein evidence" to other immune cells (T-cells), essentially saying, "Look! This heart tissue is an enemy! Attack it!"

4. The Cycle of Destruction
This false alarm triggers a chain reaction. The T-cells get angry and start attacking the heart muscle, causing inflammation and scarring. The heart gets bigger, weaker, and less efficient. This is called adverse cardiac remodeling, which leads to heart failure.

The Experiment: Proving the Theory

The researchers wanted to prove that these specific B-cells were the villains. They did a few clever experiments:

• The "Trojan Horse" Transfer: They took B-cells from mice that had already had a heart attack and injected them into healthy mice.
  • Result: The healthy mice developed heart problems, even though they never had a heart attack! This proved the B-cells carried the "bad instructions" with them.
• The "Silent" Guards: They used a special type of mouse where the B-cells had their MHC II scanners broken (deleted). These guards couldn't show the "evidence" to anyone.
  • Result: When they transferred these "silent" B-cells into healthy mice, the mice stayed healthy. The heart didn't get damaged. This proved that the scanning mechanism (MHC II) was the key to the problem.
• The Specific Squad: They found that it wasn't just any B-cell, but specifically the Follicular B-cells (a specific team within the warehouse) that were causing the trouble.

The Human Connection

The researchers didn't stop at mice. They looked at data from human patients who had heart attacks. They found that the human B-cells in these patients were also acting up, showing the same "confused scanner" activity. This suggests the same thing is happening in people.

The Takeaway: A New Way to Fix the Heart

For a long time, doctors tried to treat heart failure by trying to calm down all inflammation. But that's like trying to stop a riot by turning off the lights in the whole city—it stops the bad guys, but it also stops the good guys (the repair crew) from working.

This study suggests a much more precise solution: Target the specific "confused scanners" (MHC II) on the B-cells.

If we can develop a drug that stops these specific B-cells from showing the "wrong ID cards" to the rest of the immune system, we might be able to stop the heart from attacking itself, without shutting down the body's ability to heal.

In short: The heart attack confused the immune system's security guards. These guards traveled from the spleen to the heart and started a civil war. By disabling the guards' ability to shout the wrong orders, we might be able to save the heart.

Technical Summary

1. Problem Statement

• Clinical Context: Ischemic heart failure (HF) following myocardial infarction (MI) is driven by sustained maladaptive inflammation. While the "cardio-splenic axis" (the mobilization of immune cells from the spleen to the heart post-MI) is a known therapeutic target, the specific cellular mechanisms remain poorly understood.
• Knowledge Gap: Previous immunomodulatory trials in HF have largely failed due to an inability to selectively target maladaptive inflammation without disrupting protective repair. Specifically, the precise role of B cells within the cardio-splenic axis and their mechanism of action in driving adverse cardiac remodeling had not been systematically investigated.
• Hypothesis: The authors hypothesized that splenic B cells contribute to post-MI adverse remodeling not just via antibody production or cytokine secretion, but potentially through MHC Class II (MHC II)-mediated antigen presentation.

2. Methodology

The study employed a multi-modal approach combining in vivo murine models, adoptive transfer experiments, and high-dimensional omics technologies.

• Animal Models:

  • MI Induction: C57BL/6 mice underwent permanent left anterior descending (LAD) coronary artery ligation to induce MI. Sham surgeries served as controls.
  • Genetic Models: Used B cell-specific MHC II-deficient mice (Cd19-Cre x H2-Ab1 KO) to isolate the role of MHC II on B cells.
  • Adoptive Transfer: Splenocytes or purified splenic B cells were isolated from donor mice (4 weeks post-MI or sham) and intravenously transferred into naïve recipient mice. Recipients were monitored for up to 16 weeks.
  • Cell Sorting: Used CD45.1/CD45.2 congenic markers to track donor cell engraftment. Specific subtypes (Follicular vs. Marginal Zone B cells) were sorted via FACS.

• Omics and Molecular Analysis:

  • Single-Cell RNA Sequencing (scRNA-seq): Performed on splenic, myocardial, and peripheral blood B cells from donors and recipients (WT vs. MHC II-KO) to analyze gene expression profiles, clonality (V(D)J), and pathway enrichment.
  • MHC II Peptidomics: Mass spectrometry (LC-MS/MS) was used to isolate and sequence peptides bound to MHC II molecules on splenic B cells to identify the specific antigens being presented.
  • Cardiac Proteomics: TMT-based mass spectrometry of left ventricular tissue from recipients to assess protein-level changes in remodeling, cell death, and repair pathways.
  • Human Data Validation: Re-analysis of publicly available scRNA-seq datasets from patients with STEMI and ischemic cardiomyopathy to check for conserved pathways.

• Functional Assays:

  • Echocardiography: Serial monitoring of Left Ventricular Ejection Fraction (LVEF) and Left Ventricular End-Systolic Diameter (LVESD).
  • Histology & Gravimetry: Assessment of heart/spleen mass ratios and cardiomyocyte hypertrophy via Wheat Germ Agglutinin (WGA) staining.
  • Flow Cytometry: High-dimensional profiling of immune cell subsets in the heart and spleen.

3. Key Contributions & Results

A. Splenic B Cells Drive Adverse Remodeling

• Adoptive Transfer: Transferring unfractionated splenocytes or purified splenic B cells from MI mice into naïve recipients induced significant adverse cardiac remodeling (reduced LVEF, increased LVESD, cardiomyocyte hypertrophy) compared to sham controls.
• Persistence: The effect was progressive, observed at 4, 8, and 16 weeks post-transfer.
• Recirculation: Donor B cells (CD45.1+) were detected in the peripheral blood, spleen, and heart of recipients, confirming active recirculation between the cardio-splenic axis.

B. Mechanism: MHC II-Mediated Antigen Presentation

• Transcriptomics: scRNA-seq of splenic B cells from MI mice revealed a significant upregulation of antigen processing and presentation pathways (KEGG q-value = 8.02E-9), specifically involving MHC II components (H2-Eb1, H2-DMb1) and heat shock proteins. This was observed in follicular, germinal center, and memory B cells.
• Peptidomics: Mass spectrometry of MHC II molecules on splenic B cells from MI mice identified an enrichment of cardiac-derived peptides. Notable binders included cardiac $\alpha$-actin (ACTC1), Titin (TTN), and Myosin Heavy Chain 6 (MYH6).
• Causality (MHC II Deletion): When B cells from MHC II-deficient MI mice were transferred into naïve recipients:
  • Adverse cardiac remodeling was suppressed (LVEF and LVESD remained near normal).
  • Cardiomyocyte hypertrophy was markedly reduced.
  • Proteomic analysis showed a blunted upregulation of stress/death proteins (e.g., BAG3, UBB) and preserved expression of repair proteins (e.g., MYOM1).
• Subtype Specificity: Further experiments confirmed that Follicular B cells (not Marginal Zone B cells) were the primary drivers of this MHC II-dependent remodeling.

C. Downstream Effects on T Cells

• T Cell Modulation: scRNA-seq of myocardial immune cells in recipients showed that transfer of WT MI-B cells altered the gene expression of cardiac T cells.
• CD8 T Cell Activation: There was a significant upregulation of Interferon-gamma (IFN$\gamma$) signaling and STAT5B pathways in CD8 T cells, driven by the presence of MHC II on donor B cells.
• MHC II Dependence: In recipients of MHC II-deficient B cells, this IFN$\gamma$ signaling was downregulated, suggesting that splenic B cells activate cardiac T cells via antigen presentation, leading to tissue damage.

D. Human Relevance

• Analysis of human peripheral blood scRNA-seq data from STEMI and ischemic HF patients confirmed that antigen processing and presentation pathways (including HLA-DR, HLA-DMA, HLA-DQA) were differentially regulated in B cells, mirroring the murine findings.

4. Significance and Implications

• Novel Mechanism: This study identifies MHC II-dependent antigen presentation by splenic follicular B cells as a previously unrecognized driver of chronic heart failure post-MI. It shifts the paradigm from B cells acting solely as antibody producers to active antigen-presenting cells (APCs) that orchestrate T-cell mediated cardiac damage.
• Therapeutic Target: The findings suggest that targeting the MHC II-B cell interaction (rather than broad B-cell depletion) could be a specific therapeutic strategy to prevent adverse remodeling while preserving protective immune functions.
• Translational Potential: The conservation of these pathways in human patients with ischemic heart failure supports the clinical relevance of these findings and highlights the "cardio-splenic axis" as a viable target for immunomodulatory therapies in heart failure.
• Autoimmunity Insight: The presence of cardiac peptides on MHC II suggests a mechanism for the generation of autoimmunity post-MI, potentially occurring via BCR-independent antigen uptake of damage-associated molecular patterns (DAMPs).

In summary, the paper demonstrates that splenic follicular B cells act as a bridge between the spleen and the heart post-MI, presenting cardiac antigens via MHC II to activate cytotoxic T cells, thereby driving maladaptive cardiac remodeling. Blocking this specific antigen presentation pathway offers a promising new avenue for treating ischemic heart failure.